- Oosting SF, de Hass EC, Links TP, de Bruin D, Sluiter WJ, de Jong IJ, Hoekstra HJ, Sleijfer DT, Gietema JA. Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors. Ann Oncol 2010;21 (1): 104–108.
- Clain HJ, Pannall PR, Kotasek D, Norman RJ. Choriogonadotropin-mediated thyrotoxicosis in a man. Clin Chem 1991;37 (6): 1127–1131.
- Meister LH, Hauck PR, Graf H. Hyperthyroidism due to secretion of human chorionic gonadotropin in a patient with metastatic choriocarcinoma. Arq Bras Endocrinol Metabol 2005;49 (2): 319–322.
- Hershman JM. Physiological and pathological aspects of the effect of human chorionic gonadotropin on the thyroid. Best Pract Res Clin Endocrinol Metab 2004;18 (2): 249–265.
- Kohler S, Tschopp O, Jacky E. Paraneoplastic hyperthyroidism. BMJ Case Rep 2011;2011: 1–3.
- Goldman L, Schafer AI. Testicular cancer. In Goldman L, Schafer AI, eds. Goldman-Cecil Medicine, 25th ed. New York: Elsevier, 2016.
- Lockwood CM, Grenache DG, Gronowski AM. Serum human chorionic gonadotropin concentrations greater than 400,000 IU/L are invariably associated with suppressed serum thyrotropin concentrations. Thyroid 2009;19 (8): 863–868.
- Heda P, Cushing G. Testicular choriocarcinoma presenting as hyperthyroidism. Am J Med 2013;126 (11): e1–e2.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 29, 2016 - Issue 1